Delivery Order SPE2DB20D3103-SPE2DB25FP6M7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,056.52 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on July 21, 2025, with completion targeted for July 22, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $45,611.82 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed price delivery order was issued without set-aside provisions and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a standard pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $17,178.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60 count) on July 21, 2025, with a completion date of July 22, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $10,308.12 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with a completion date of July 22, 2025, and performance location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a relatively small transaction within the company's extensive federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $16,372.36 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) under a firm fixed price contract. The award was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside, competitively awarded procurement. Performance will be completed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $7,924.38 on July 18, 2025, for the supply of Eliquis 5 mg tablets (60-count). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and calls for ultimate completion by July 21, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Eliquis 5 mg tablets (60-count units) valued at $14,873.42 under a firm fixed-price contract. This non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements, with performance to be completed by July 21, 2025, and fulfillment from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $13,452.67. This firm fixed-price delivery order is scheduled for completion by July 21, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued without set-aside restrictions, drawing from AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order valued at $5,065.32 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-unit package) with a completion date of July 21, 2025. This firm fixed-price, non-set-aside contract was executed on July 18, 2025, with performance to be completed at the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal pharmaceutical supply...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a contract ceiling value of $50,289.43. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6M7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,087.41 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packages) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a pediatric pharmaceutical supply requirement for federal military and healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for the Defense Logistics Agency's Medical Supply Chain and fulfills this order from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. That prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply a broad range of pharmaceutical products, medical supplies, vaccines, and specialty medications to support military healthcare programs worldwide. The company's federal procurement portfolio demonstrates consistent competitively awarded contract success across multiple therapeutic domains, positioning it as a key supplier for Defense Health Agency, U.S. Coast Guard, and other government healthcare system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.1k | 7/25/25 |